tadalafil has been researched along with Pulmonary Veno Occlusive Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, Y; Zhang, L; Zhang, R | 1 |
| Chaumais, MC; Humbert, M; Jaïs, X; Montani, D; Natali, D; Price, LC; Savale, L; Simonneau, G; Sitbon, O | 1 |
1 review(s) available for tadalafil and Pulmonary Veno Occlusive Disease
| Article | Year |
|---|---|
Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Topics: Algorithms; Carbolines; Humans; Hypertension, Pulmonary; Imidazoles; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Pulmonary Veno-Occlusive Disease; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2009 |
1 other study(ies) available for tadalafil and Pulmonary Veno Occlusive Disease
| Article | Year |
|---|---|
Good response to pulmonary arterial hypertension-targeted therapy in 2 pulmonary veno-occlusive disease patients: A case report.
Topics: Adult; Antihypertensive Agents; Diagnostic Errors; Drug Therapy, Combination; High-Throughput Nucleotide Sequencing; Humans; Male; Phenylpropionates; Protein Serine-Threonine Kinases; Pulmonary Arterial Hypertension; Pulmonary Veno-Occlusive Disease; Pyridazines; Tadalafil; Vasodilator Agents | 2021 |